Drug Pipeline

FPI-2265 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12

Active Studies

Recruiting

Phase 3

Top Sponsors

What Changed in the Last 30 Days

First Posted	New Trial Filing	Phase	Status
2026-05-28	NCT07611110 AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant…	Phase 3	Recruiting
2026-05-15	NCT07590934 Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic…	Phase 1/2	Not Yet Recruiting

Active Studies by Phase

Phase 3

Phase 2

Phase 1/2

Active Trials

NCT ID	Title	Condition	Status
Phase 3
NCT07611110	AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant…	Metastatic Castration-resistant Prostate Cancer	Recruiting
Phase 2
NCT05219500	Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of…	Metastatic Castration Resistant Prostate Cancer	Active, Not Recruiting
NCT06402331	FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant…	Metastatic Castration-resistant Prostate Cancer	Active, Not Recruiting
NCT06909825	FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant…	Metastatic Castration-resistant Prostate Cancer	Active, Not Recruiting
Phase 1/2
NCT07590934	Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic…	Metastatic Prostate Cancer	Not Yet Recruiting

Sponsors Running FPI-2265 Trials

Fusion Pharmaceuticals Inc. (3) AstraZeneca (2)

Disease Areas

Prostate Cancer (5)

Get alerts when FPI-2265 trials change

Status changes, date slips, and new filings — detected daily, delivered to your inbox.